There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMD – Research Report) and PROCEPT BioRobotics (PRCT – Research Report) with bullish sentiments.
Cormedix (CRMD)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Cormedix, with a price target of $19.00. The company’s shares closed last Tuesday at $3.40.
According to TipRanks.com, Butler is a 1-star analyst with an average return of
Currently, the analyst consensus on Cormedix is a Strong Buy with an average price target of $14.33.
See Insiders’ Hot Stocks on TipRanks >>
PROCEPT BioRobotics (PRCT)
TD Cowen analyst Josh Jennings reiterated a Buy rating on PROCEPT BioRobotics today and set a price target of $59.00. The company’s shares closed last Tuesday at $47.95, close to its 52-week high of $52.32.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Currently, the analyst consensus on PROCEPT BioRobotics is a Strong Buy with an average price target of $56.67, which is a 18.9% upside from current levels. In a report issued on February 28, Truist Financial also assigned a Buy rating to the stock with a $58.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRMD:
- Options Volatility and Implied Earnings Moves Today, March 12, 2024
- CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
- CorMedix Announces DefenCath Launch and CMS Benefit Approval
- CorMedix Inc. Announces Commercial and Reimbursement Updates
